# Semaglutide Half Life and Pharmacokinetics: The One-Week Number Explained

> Semaglutide half life is about one week (~165-168 hours), with clearance roughly five weeks after the last dose. The pharmacokinetics — albumin binding, DPP-4 resistance, AUC/Cmax — explained and cited.

Why the elimination half-life is about a week, what that means for clearance, and the chemistry that produces it.

## The short version

The semaglutide half life is about one week. "Half-life" is the time it takes for the amount of drug in your blood to drop by half. For semaglutide that is roughly 165 to 168 hours — around seven days — which is extraordinarily long for a peptide. The natural hormone it copies is gone in about two minutes.

That one number drives almost everything else. Because it takes a week for levels to halve, a single injection lasts a week, which is why the drug is dosed once weekly. It also means the drug clears the body slowly: it takes roughly five weeks after the last dose for it to be effectively gone. The long half-life is not an accident — it is built into the molecule by two chemical tricks that stop the body from breaking it down or flushing it out. The rest of this page explains those tricks and what the pharmacokinetic studies measured.

## The elimination half-life and clearance

The elimination half-life of semaglutide is approximately one week, commonly cited as about 165-168 hours, for both the subcutaneous and oral formulations [13][15]. With first-order elimination, effectively complete clearance follows roughly five weeks (about five half-lives) after the final dose [15]. A 2024 systematic review of semaglutide pharmacokinetics confirmed this long half-life as the basis for once-weekly subcutaneous administration and characterized AUC (total drug exposure over time), Cmax (peak concentration), time-to-Cmax, and clearance across formulations and studies [13]. This is the defining pharmacokinetic property of the molecule.

## Why it lasts: albumin binding and DPP-4 resistance

Two engineered features produce the long half-life. First, an alpha-aminoisobutyric-acid (Aib) substitution at position 8 blocks dipeptidyl peptidase-4 (DPP-4) — the enzyme that degrades native GLP-1 within minutes — so the peptide survives in circulation [15]. Second, a C18 fatty-di-acid side chain, attached via a glutamic-acid/ADO spacer to the single lysine at position 26, binds strongly but reversibly to serum albumin [15]. Albumin is the most abundant protein in blood; by riding on it, semaglutide is shielded from renal filtration and metabolism, and is released slowly back into free circulation. Reversible albumin binding plus DPP-4 resistance is the structural recipe for once-weekly dosing.

## What the half-life means for dosing

Because levels fall by half only once per week, a once-weekly subcutaneous dose maintains relatively steady exposure between doses, and steady-state concentrations build over several weeks of repeated dosing [13][15]. The same long half-life is why titration is slow — the documented ladders step the dose up over months [1][15] — and why washout is long: label guidance advises discontinuing roughly two months before a planned pregnancy, reflecting the ~5-week clearance plus a safety margin [15]. The half-life is the through-line connecting the chemistry, the weekly interval, the slow titration, and the long washout.

## Oral versus subcutaneous pharmacokinetics

Both formulations share the long elimination half-life, but they differ sharply in absorption. The subcutaneous injection is well absorbed; the oral tablet relies on the absorption enhancer SNAC and achieves a bioavailability of only about 0.4-1%, which is why it must be taken fasted with minimal water [15][23]. Day-to-day exposure with the oral tablet is therefore more sensitive to administration technique than the injection. The pharmacokinetic review summarizes both routes within one framework [13]; the practical implications of the oral route are detailed on the [oral semaglutide](/oral) page.

---

A documentation-grade reading of the semaglutide literature, indexed by half-life and dose; not a clinic, not a pharmacy, and nothing here prescribed or dispensed.